JP2005508165A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508165A5
JP2005508165A5 JP2003534444A JP2003534444A JP2005508165A5 JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5 JP 2003534444 A JP2003534444 A JP 2003534444A JP 2003534444 A JP2003534444 A JP 2003534444A JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acids
polynucleotide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003534444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508165A (ja
JP4383869B2 (ja
Filing date
Publication date
Priority claimed from US09/972,599 external-priority patent/US7119165B2/en
Application filed filed Critical
Publication of JP2005508165A publication Critical patent/JP2005508165A/ja
Publication of JP2005508165A5 publication Critical patent/JP2005508165A5/ja
Application granted granted Critical
Publication of JP4383869B2 publication Critical patent/JP4383869B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003534444A 2001-10-06 2002-10-04 軸索成長のnogoのレセプターを仲介とした妨害 Expired - Fee Related JP4383869B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/972,599 US7119165B2 (en) 2000-01-12 2001-10-06 Nogo receptor-mediated blockade of axonal growth
PCT/US2002/032007 WO2003031462A2 (en) 2001-10-06 2002-10-04 Nogo receptor-mediated blockade of axonal growth

Publications (3)

Publication Number Publication Date
JP2005508165A JP2005508165A (ja) 2005-03-31
JP2005508165A5 true JP2005508165A5 (enExample) 2006-01-05
JP4383869B2 JP4383869B2 (ja) 2009-12-16

Family

ID=25519870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003534444A Expired - Fee Related JP4383869B2 (ja) 2001-10-06 2002-10-04 軸索成長のnogoのレセプターを仲介とした妨害

Country Status (6)

Country Link
US (6) US7119165B2 (enExample)
EP (1) EP1451337A4 (enExample)
JP (1) JP4383869B2 (enExample)
AU (1) AU2002334889B2 (enExample)
CA (1) CA2461655A1 (enExample)
WO (1) WO2003031462A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264174A3 (en) * 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
DE60141409D1 (de) * 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
MXPA05001615A (es) * 2002-08-10 2005-08-19 Biogen Idec Inc Antagonistas del nogo receptor.
JP2006526382A (ja) * 2002-12-06 2006-11-24 シンガポール ジェネラル ホスピタル ピーティーイー リミテッド 中枢神経系の損傷
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
US7541335B2 (en) * 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
AU2004231742A1 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
CN101410130A (zh) * 2003-05-15 2009-04-15 利兰·斯坦福青年大学托管委员会 新颖的免疫调节肽
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
WO2005059515A2 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
AU2005210621B2 (en) * 2004-01-30 2009-10-01 Biogen Idec Ma Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
JP2008500064A (ja) * 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006047049A2 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis
EP1904091A4 (en) * 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2007014382A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant nogo-66 domain proteins
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007025219A2 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
EP1928905B1 (de) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
EP2023735A4 (en) * 2006-05-15 2011-05-25 Biogen Idec Inc USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES
EP2046828A2 (en) * 2006-07-07 2009-04-15 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8642040B2 (en) 2006-07-24 2014-02-04 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
JP2010502623A (ja) * 2006-08-31 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Nogoレセプターポリペプチドの末梢投与に関する方法
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
WO2009073141A2 (en) * 2007-11-28 2009-06-11 Strittmatter Stephen M Nogo receptor binding small molecules to promote axonal growth
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8992918B2 (en) * 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Lingo抗体または断片を含む組成物
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 rgm a 단백질에 대한 모노클로날 항체
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341050C (en) * 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
AU652537B2 (en) * 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
WO2000070050A1 (en) 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
US6962797B2 (en) * 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
EP2264174A3 (en) 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
HUP0301829A3 (en) 1998-11-06 2009-03-30 Schwab Nucleotidok and protein sequences of nogo genes and methods based thereon
US6152155A (en) 1998-11-30 2000-11-28 Milligan; Lon Filter cleaning device
ATE458050T1 (de) 1998-12-01 2010-03-15 Genentech Inc Promotion oder inhibition von angiogenese und kardiovaskularisation
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
AU2883600A (en) 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」
AU6394400A (en) 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
PL356887A1 (en) 2000-01-12 2004-07-12 Yale University Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
DE60141409D1 (de) * 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
JP2005507246A (ja) 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Nogoレセプターホモログおよびそれらの使用
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Nogoレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US20030113325A1 (en) * 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (en) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
MXPA05001615A (es) * 2002-08-10 2005-08-19 Biogen Idec Inc Antagonistas del nogo receptor.
AU2004231742A1 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US20080274112A1 (en) 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
CA2535007A1 (en) 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
AU2005210621B2 (en) 2004-01-30 2009-10-01 Biogen Idec Ma Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
US8992918B2 (en) 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury

Similar Documents

Publication Publication Date Title
JP2005508165A5 (enExample)
JP2003519481A5 (enExample)
JP6807893B2 (ja) α−シヌクレインを認識するヒト化抗体
KR101681910B1 (ko) Rgm a 단백질에 대한 모노클로날 항체 및 이의 용도
ES2272093T5 (es) Composiciones y métodos para incrementar la mineralización de la substancia ósea
US9133272B2 (en) Bispecific binding agents
EP1181318B1 (en) Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
JPH11170A5 (enExample)
AU2018225493B2 (en) Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
KR101484025B1 (ko) 염증성 질환의 치료를 위한 cxcl13 길항제 및 이의 용도
CA2872928C (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
HRP20180516T1 (hr) Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida
JP2009520691A5 (enExample)
EA014525B1 (ru) Антитела к склеростину и способы их применения
EA015166B1 (ru) Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
JP2019527194A5 (enExample)
JP2008509658A5 (enExample)
RS57315B1 (sr) Humanizovana antitela koja prepoznaju alfa-sinuklein
KR20240046648A (ko) 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
JP2008509152A5 (enExample)
JP2020517262A5 (enExample)
JPH08504086A (ja) 背側組織作用因子及び組成物
JP2012508027A5 (enExample)
AU2010209273A1 (en) Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
RU2007146455A (ru) Варианты эритропоэтина